MannKind Presents Positive Afrezza® Clinical Data from Type 1 Diabetes Study at 55th Annual Meeting of the EASD
(World News Science)

MannKind Presents Positive Afrezza® Clinical Data from Type 1 Diabetes Study at 55th Annual Meeting of the EASD September 19, 2019 WESTLAKE VILLAGE, Calif., Sept. 19, 2019 (GLOBE NEWSWIRE) --MannKind Corporation (NASDAQ: MNKD) announced that data from a one-year study of Afrezza® (insulin human) Inhalation Powder was presented at the 55 th Annual Meeting of the European Association for the Study of Diabetes (EASD) in Barcelona, Spain. Oral Abstract 183: Technosphere Insulin Provides Better Early Postprandial Glucose Control than Subcutaneous Rapid-Acting Analog MannKind investigators reported data1 from more than 500 patients with type 1 diabetes comparing Afrezza to rapid-acting injected...